Ligand is a high-quality pharmaceutical royalty franchise with a wide economic moat, elite margins, and a strong multi-quarter earnings track record, but the stock has reached its analyst price target leaving just 0.2% of upside at current levels — and a high-severity single-supplier dependency creates a meaningful concentration risk that warrants patience before adding exposure.
Thesis pillars
- Wide Moat Elite Quality↓Deteriorating
- Price At Take Profit No Upside↓Deteriorating
- Single Supplier Concentration Risk↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 27, 2026· older than 90 days
Ligand Pharmaceuticals Incorpor (LGND) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $307.02, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Hovione; Analyst target reached - limited upside remaining.
Ligand Pharmaceuticals acquires and structures royalty interests in mid- to late-stage biopharmaceutical products, operating as a royalty aggregator rather than a drug developer. The company collected $176.9 million in 2025 royalty receipts from 12 major commercial assets... Read more
Hold if already holding. Not a fresh buy at $307.02, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Hovione; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news boost analyst 0.60, earnings proximity 113d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Ligand Pharmaceuticals Incorpor
About Ligand Pharmaceuticals Incorpor
Ligand Pharmaceuticals collected $176.9 million in 2025 royalty receipts across 12 major commercial-stage assets, led by Kyprolis (Amgen, $35.5 million), Qarziba (Recordati, $33.7 million), and Filspari (Travere, $32.0 million). Captisol material sales add further revenue, representing approximately half of the company's royalty revenues, and the Captisol portfolio spans 17 FDA-approved products protected by patents through at least 2033.
Ligand generates revenue through four mechanisms: royalty purchases on existing royalty contracts from inventors and institutions; acquisitions of companies with embedded royalty rights (including Apeiron for Qarziba and Pfenex for five commercial royalty programs including Capvaxive, Vaxneuvance, and Rylaze); development-stage financing in exchange for synthetic royalties; and operation of the Captisol and NITRICIL technology platforms. The company does not manufacture drugs directly; commercial partners including Amgen, Merck, Recordati, Jazz, and Baxter handle manufacturing and distribution. Captisol is manufactured exclusively by Hovione at facilities in Ireland and Portugal, with supplementary processing capacity in the U.S. and England. In 2025, the company deployed $50 million in Castle Creek Biosciences for D-Fi (Phase 3 gene therapy), $25 million in Orchestra BioMed for cardiology programs, and $7 million in Arecor for two partnered programs. Generic entry for Evomela commences June 1, 2026 per a settlement with Teva.
Show full overview
Ligand sources all Captisol from Hovione's facilities in Ireland and Portugal—named as the sole supplier in the 10-K—with no guaranteed alternate source available in adequate time if supply were interrupted. Captisol's morphology patents expired in 2026 in the U.S., though low-chloride patents extend to 2033 and high-purity patents to 2029. In April 2026, the company terminated the TR-Beta Program with Viking Therapeutics via Form 8-K, citing Viking's alleged material breach—demonstrating that partner agreements underlying royalty streams may end before their natural horizon.
See also: Healthcare · Biotechnology
From Ligand Pharmaceuticals Incorpor's most recent 10-K filing, extracted June 11, 2026.
Recent developments
No fresh coverage since Sep 16, 2026
Recent Developments — Ligand Pharmaceuticals Incorpor
Latest news
- NEWS TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits — Stocktwits Sep 16, 2026 positive
- NEWS TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - stocktwits.com — stocktwits.com Sep 16, 2026 positive
- NEWS Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital - Yahoo Finance — Yahoo Finance Aug 26, 2026 positive
- NEWS Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com Canada — Investing.com Canada Aug 26, 2026 positive
- NEWS Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com UK — Investing.com UK Aug 26, 2026 positive
Latest item Sep 16, 2026 · Generated 2026-11-03T11:59:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierHovione10-K Item 1A: 'Our ability to source Captisol from our sole supplier may be impacted by a supply interruption ... We obtain Captisol from Hovione, our third-party manufacturer'
- MEDIUMProductCaptisol10-K Item 1A: 'Revenues from sales of Captisol material to our collaboration partners, including Amgen, represent approximately half of our royalty revenues.'
- MEDIUMProductKyprolis10-K Item 1A: 'A significant portion of our royalty revenue is based on sales of Kyprolis by Amgen'
Material Events(8-K, last 90d)
- 2026-04-30Item 1.02MEDIUMApril 24, 2026: Ligand terminated the TR-Beta Program (VK2809, VK0214) under the Master License Agreement with Viking Therapeutics, citing Viking's alleged material breach of its obligation to use commercially reasonable efforts. Effective May 4, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Revenue shrinking — -31.8% YoY. Growth thesis broken unless recovery story develops.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $307.02, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Hovione; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Analyst target $305.30 reached (−0.6%), stop $285.53 (−7.5%), A.R:R -0.1:1. Score 5.2/10, moderate confidence.
Analyst target $305.30 reached (−0.6% from $307.02); no take-profit level is published. Analyst target $305.30 reached (−0.6%), stop $285.53 (−7.5%), A.R:R -0.1:1. Stop-loss: $285.53.
Concentration risk — Supplier: Hovione; Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0).
Ligand Pharmaceuticals Incorpor trades at a P/E of 32.4 (forward 25.7). TrendMatrix value score: 4.0/10. Verdict: Hold.
17 analysts rate LGND, with a consensus score of 4.4/5. 12 analysts publish price targets averaging $351.
What does Ligand Pharmaceuticals Incorpor do?Ligand Pharmaceuticals acquires and structures royalty interests in mid- to late-stage biopharmaceutical products,...
Ligand Pharmaceuticals acquires and structures royalty interests in mid- to late-stage biopharmaceutical products, operating as a royalty aggregator rather than a drug developer. The company collected $176.9 million in 2025 royalty receipts from 12 major commercial assets including Kyprolis (Amgen), Qarziba (Recordati), and Filspari (Travere), plus Captisol material sales and licensing fees.